Ph.D., biology, Baylor College of Medicine; M.S., biostatistics, Harvard T.H. Chan School of Public Health; B.S., biological science and biotechnology, Tsinghua University, China
Summary of Experience
Dr. Zhao draws on her background in biology and biostatistics in her research on the value of health care products and her work on analytics across the product life cycle. She has broad experience with the development and implementation of health economics and outcomes research (HEOR) strategies in a number of therapeutic areas, including diabetes, oncology, immunology, infectious diseases, and hematology. Dr. Zhao applies advanced research methods for health care data to real-world evidence development, individualized medicine, predictive analytics, and cost-effectiveness analysis. Her work has been used to inform health care regulators and payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences.
Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome
Therapeutics and Clinical Risk Management. 2018 Jul 25;14:1267-1277
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
BMJ Open. 2018 Aug 17;8(8):e021642
Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy. Jun 2017;8(3):555-571
Antimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.